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Summary
Background Aspirin-exacerbated respiratory disease is under-diagnosed and therefore
effective and inexpensive therapy with aspirin desensitization is rarely performed.
Methods We present an audit of 150 patients with difﬁcult to treat nasal polyposis, 132
of whom also had asthma, 131 of whom underwent challenge with the only soluble form
of aspirin, lysine aspirin (LAS), to conﬁrm or exclude the diagnosis of aspirin-exacerbated
respiratory disease (AERD).
Results One hundred patients proved positive on nasal challenge, 31 who were negative
went onto oral LAS challenge and a further 14 gave positive results, leaving 17 who were
negative to a dose equivalent to over 375 mg of aspirin. Nineteen were not challenged
because of contraindications.
With the exception of one patient who developed facial angioedema and two patients
with > 20% drop in FEV1 (following nasal plus oral challenge) no other severe adverse
events occurred. No hospitalization was required for these three patients.
Nasal inspiratory peak ﬂow monitoring was less sensitive to obstruction caused by
aspirin than was acoustic rhinometry – which should be employed when aspirin challenge
is an outpatient procedure.
Conclusions Provided patients are carefully chosen and monitored LAS challenge is suit-
able for ENT day case practice where respiratory physician help with asthma is available
and should reduce the under-diagnosis of this condition.
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Introduction
Aspirin-Exacerbated Respiratory Disease (AERD) con-
sists of asthma, nasal and sinus polyps and a respira-
tory sensitivity to aspirin and non-steroidal anti-
inﬂammatory drugs [1]. Patients with this syndrome,
often referred to as aspirin triad or Samter’s triad, have
progressive inﬂammatory disease of the upper and
lower respiratory tracts [2]. The prevalence of aspirin
sensitivity ranges from 0.6% to 2.5% of the general
population and between 2% and 23% in asthmatic indi-
viduals [3, 4]. The prevalence of aspirin sensitivity in
patients with asthma and nasal polyposis has been esti-
mated at 25.6% [5]. AERD is therefore not rare in ENT
practice since many patients present with initial nasal
symptoms, often non-allergic rhinitis,succeeded by
nasal polyposis: often severe with a CT scan ‘white out’
and rapidly recurrent following surgery [6]. It is how-
ever under-diagnosed. The nasal polyp size and the
degree of mucosal inﬂammation are more extensive in
aspirin-sensitive than in aspirin-tolerant patients [2].
The clinical history alone is not a reliable tool for diag-
nosing hypersensitivity to aspirin [7] as many asthma
patients are advised to avoid aspirin, or the reaction
may have occurred many years before and other drugs
may have also been taken at the same time. It has been
shown that patients with AERD are not solely aspirin-
sensitive but their reactivity is to COX-1 inhibitors in
general, so reactions occur to many non-steroidal anti-
inﬂammatories [1, 8].
There is a need to diagnose aspirin sensitivity: to
warn patients accurately about avoidance, to enable the
non-sensitive to use therapeutic aspirin and NSAIDS
and to employ aspirin desensitization in those who are
sensitized.
Unfortunately, there is no suitably sensitive and spe-
ciﬁc in vitro test [9] so drug challenge has to be
employed, except where there is a history of recentingestion without problems (negative) or of adverse
reaction to two different NSAID molecules (positive).
Oral or bronchial challenge, starting with a very low
dose, usually around 30 mg, and then giving gradually
increasing doses can be used [10]. Although bronchial
challenge can take only 4 h to perform [11], both these
methods can result in severe symptoms in over 50% of
subjects, especially asthma, and may require hospital
admission, emergency treatment, an intravenous line
and close monitoring. Since the reaction can be delayed
the challenge often requires more than 1 day and thus
admission of the subject overnight.
An alternative method, introduced in the 1990s, is
that of initial nasal challenge using the only truly sol-
uble form of aspirin, lysine aspirin(L-ASA) [12]. This
has the advantage that the challenge is directly aimed
at possibly aspirin-sensitive polyp tissue. This method
is particularly relevant for patients who present to
ENT/Rhinology clinics suffering from severe upper air-
way symptoms resistant to medical treatment and
multiple nasal operations. Highly aspirin-sensitive
patients should react at low doses with mainly nasal
symptoms with very little asthma exacerbation. The
less sensitive who tolerate the initial nasal doses are
unlikely to be severely affected when they react to
subsequent oral challenge. The aim of this study was
as follows:
￿ To explore the feasibility, safety and efﬁciency of
this method if carried out in a day case setting by
experienced staff members.
￿ To establish the ﬁrst step towards a local nasal aspi-
rin desensitization programme. We report our experi-
ence with this method.
Patients
One hundred and ﬁfty subjects were recruited from our
tertiary Rhinology clinic, in which patients with com-
plex respiratory disease are seen. All were symptomatic
despite conventional therapy with saline nasal douch-
ing, topical corticosteroids and, where effective, leuko-
triene antagonists. One hundred and twenty had
undergone sinus surgery with a mean of 3.8 operations.
Two had non-allergic rhinitis, the remainder had
chronic rhinosinusitis with nasal polyposis. Asthma was
associated in 132. Seven had a deﬁnitive history of
AERD and underwent challenge preparatory to desensi-
tization, 86 had a suggestive history (reaction to one
NSAID only or a doubtful reaction) and 53 had not
taken any recent aspirin or NSAID (four had tolerated
one NSAID, but not within 6 months).
Intranasal corticosteroids were stopped for 1 week
prior to challenge, all other treatments, especially anti-
asthma therapy and including montelukast [13] were
continued.
Exclusion criteria
Since polyp expansion and nasal airway monitoring
[10, 12, 14] is vital to assess the reaction, patients with
grade 3 or larger polyps were treated, either medically
with oral corticosteroids and betamethasone drops, or
surgically, to reduce polyp size prior to the challenge.
At least a month was permitted to elapse between polyp
reduction and subsequent challenge.
Patients younger than 18 years and older than
65 years of age were excluded. Those with a deﬁnite
history of anaphylaxis or of urticaria/angioedema to
aspirin were also excluded, as were those who had a
reaction occurring within a few minutes, as this was
likely to be IgE-mediated. Those who recently (last
6 months) tolerated aspirin or a Cox 1 NSAID were
regarded as tolerant and were not challenged. Patients
with chronic urticaria and patients with unstable car-
diovascular conditions or severe or unstable/brittle
asthma (FEV1 < 65% on preventative inhalers) were
excluded. Patients with uncontrolled asthma were later
included if asthma control had been established by
guideline – directed treatment. A decision algorithm is
given in Fig. 1.
Control subjects
Six non-rhinitic, non-asthmatic control subjects (3
males, age range 35–65) were tested with 60 mg nasal
lysine aspirin as a single dose, following a negative sal-
ine challenge.
Methods
Ethics
Ethical approval was unnecessary for this audit of our
routine diagnostic practice; however, in fact all the sub-
jects received written information at least one week
beforehand and signed a consent form which included
aspirin challenge to take part in a study of the genetics
of aspirin hypersensitivity which will be reported later.
Subjective evaluation
Each patient assessed symptoms of running, blocking,
itching and sneezing, experienced before and during
the challenge using a validated 10 cm visual analogue
scale.
Objective evaluation
Nasal endoscopy. A rigid nasal endoscope with 0° or
30° angle was gently inserted into each nostril, examin-
ing the inferior and middle meatus, nasopharynx, septal
© 2013 The Authors. Clinical & Experimental Allergy Published by John Wiley & Sons, Ltd., Clinical & Experimental Allergy, 43 : 874–880
LAS challenge in nasal polyposis 875anatomy and endonasal mucosal state and noting the
grade of polyps in each nostril according to the Lund–
Kennedy score [15].
Acoustic rhinometry. The nasal airway was monitored
using the acoustic rhinometer according to the guide-
lines for nasal challenge [16]. This is a measure of nasal
patency, measuring echoes of sound impulses sent into
one nostril. The measurement provides information on
the nasal luminal anatomical structures, either as a
measure of nasal volume over a standard distance into
the nostril or as the minimal cross-sectional area within
the nasal cavity. The measurement was performed in
each nasal cavity separately but the combined score
was used to assess changes in patency, both at the min-
imal cross-sectional area (A min) and also using the
total nasal volume from 0 to 12 cm.
Nasal inspiratory peak ﬂow
This was measured using the Youlten peak ﬂow meter
(Clement Clark International), which is attached to an
anaesthesia mask which was chosen for each patient so
that it was not too large preventing leakage of air, nor
too small compressing the nose with impairment of
nasal inspiration.
The patient was asked to blow the nose at the begin-
ning of the study then to exhale maximally, after which
the mask was placed over the nose and mouth with an
airtight seal. The patient was then asked to inspire
forcefully through the nose with closed lips. Lip closure
was veriﬁed during the PNIF test by inspection through
the transparent anaesthesia mask.
The nasal ﬂow was expressed in litres per minute,
and consecutive measurements were performed taking
the best of three outcomes [17].
Patients with Nasal Polyps & Asthma
Difficult to control
Recent 300 mg Aspirin/NSAID 
ingestion without problems
Aspirin tolerant
Respiratory reaction to Aspirin 
and different Cox-1 inhibitor 
NSAID
Aspirin sensitive
One reaction to aspirin/NSAID
or no recent ingestion
Consider LAS challenge
￿ Immediate reaction in 10 
minutes?
￿ Anaphylaxis/laryngeal 
swelling?
￿ Urticaria/angioedema?
Unsuitable YES
Grade 3 or worse polyps?
Uncontrolled asthma?
NO
YES
Treat and reduce polyps
Obtain asthma control
NO
￿ Inform patient of risks and 
methodology.
￿ Consent form given
￿ Advise to stop intranasal 
steroids one week before 
challenge.
LAS challenge at next visit
Fig. 1. Decision algorithm for consideration of lysine aspirin nasal challenge.
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Lower respiratory function was evaluated using a spi-
rometer (Model Vitalograph 2160, Maids Moreton, UK),
complying with the European Respiratory Society Rec-
ommendations. The FVC (% predicted), FEV1 (% pre-
dicted) and FVC/FEV1 (%) were recorded. A drop of
20% FEV1 was considered positive.
Placebo
0.9% saline solution at room temperature from freshly
opened 5–10 mL ampoules was used.
Lysine aspirin
A solution of 900 mg of lysine aspirin (Sanoﬁ, Paris,
France) – which is equivalent to 500 mg of acetyl sali-
cylic acid (aspirin) – was freshly prepared at the start of
the procedure by dissolving the contents of one sachet
(ASPEGIC 500 mg, Sanoﬁ – Aventis, Ditto, France) in
10 mL saline. Lysine aspirin is known to be more water
soluble than aspirin (40% vs. 0.3%) and is non-irritant.
Fresh supplies were made after 4 h since the solution is
unstable.
Challenge procedure
The patient sat quietly in the laboratory for an initial
stabilization period of 15 min then baseline measure-
ments of symptoms, nasal airway and lower airway
were taken. An initial single blind challenge with nor-
mal saline, as placebo, was carried out administering
100 lL each side via a pipette with the patient in the
head upside down position for 1 min, as the drops are
delivered directly to the polyps in this way. Delivering
the solution via a pipette was found to be more accu-
rate than spray delivery.
After 15 min, further symptom scores and readings
were made and if the change on acoustic rhinometry
was greater than 25% decrease in Amin the challenge
was abandoned as the nasal hyper-reactivity was too
severe to permit accurate diagnosis. The patient was
given further more intense anti-inﬂammatory treatment
to reduce hyper-reactivity and re-booked for repeat
challenge at least a month later. If the placebo chal-
lenge did not cause a signiﬁcant reduction in the nasal
airway then graduated challenge with lysine aspirin
was performed using initial doses of 5–10 mg applied
as 100 lL in drop form in the head upside down posi-
tion, one to each nostril, after which the patient
remained with head upside down for 1 min. Re-assess-
ment was made at 45 min, and if no signiﬁcant change
had occurred a double dose was administered with fur-
ther readings after 45 min. If the patient was symptom-
atic and changes had occurred, but did not reach those
needed for a positive challenge then a further set of
readings was made after a further interval of 15–
30 min. This process was repeated using doses of
20 mg, then 40 mg intranasally according to the algo-
rithm (Fig. 2). The maximal cumulative nasal dose was
usually 75–100 mg.
Patients who were negative at the nasal provocation
were challenged sublingually with increasing doses of
aspirin to reach the cumulative doses of at least
350 mg of aspirin.
Criteria for a positive challenge response
The criteria were taken from the deﬁnitive paper on
aspirin challenge [10] and were as follows: Increased
symptoms [see Fig. 1 recorded by VAS, plus either 25%
or greater decrease in the nasal airway (represented by
a reduction of cross-sectional area: Amin or volume 0–
12 cm)] as assessed by acoustic rhinometry or a 40%
decrease in nasal inspiratory peak ﬂow.
Reproducibility of the nasal challenge was assessed
by a second challenge in 83 patients who took a second
nasal application of lysine aspirin 24 h later at the dose
to which they were previously positive.
Results
Six non-rhinitic, non-asthmatic control subjects (3
males, age range 35–65) tested with 120 mg nasal
lysine aspirin reported initial mild irritation, lasting
under 2 min. No other upper or lower airway symptoms
or changes occurred.
One hundred and ﬁfty patients [76 men and 74
women; mean age 47  13 (SD) years] with chronic
rhinosinusitis were recruited from the Rhinology Clinic
at the Royal National Throat, Nose and Ear Hospital,
London, from 2002 to Spring 2010. Written formal con-
sent was obtained from all the patients. One hundred
were positive on nasal challenge at the doses indicated
in Fig. 3. There was a 71% correlation between the pro-
voking dose on history and the dose at positive chal-
lenge in those with a history of a reaction to aspirin.
Fourteen who were negative on nasal challenge
were positive when challenged with higher doses
orally – see Fig. 3. Of these, four had to return on a
second outpatient visit to complete the challenge,
which was re-started at the last previously tolerated
dose. Seventeen patients (13%) were ASA tolerant
with negative challenge test. Nineteen patients were
not challenged as they did not fulﬁl the inclusion
criteria.
All positive patients reacted with nasal symptoms.
These were treated with nasal decongestants and topical
nasal steroids. Twenty-one patients also developed mild
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chospam and /or chest tightening,and were treated with
beta 2 agonists and inhaled corticosteroid. Two patients
with a greater than 20% drop in FEV1 following nasal
plus oral challenge were given oral corticosteroid for
3 days in addition.
Seven patients noted symptoms outside the respira-
tory tract: mild facial itching, urticaria and mild facial
angioedema (one patient, see below), with no previous
history of these. No one required adrenaline.
One individual had a positive history of aspirin sensitiv-
ity, but was negative on challenge. One individual who
had not previously suffered this symptom required brief
oral corticosteroid (30 mg/day for 3 days) therapy for
facial angioedema. In retrospect, it was realized that as he
had grade 3 polyps at the start of challenge any response
Suitable patient 
Hypersensitive 
Unsuitable 
Treat and retry later 
YES 
WAIT 15 MINUTES
Initial readings * 
WAIT 15 MINUTES FOR EQUILIBRATION 
Saline challenge 
100 μl each nostril 
Baseline readings * 
NO
Dissolve 500 mg aspirin
(900 mg lysine aspirin) in 
10 ml saline 
5 mg (100 μl to each nostril) in 
head upside down position 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal vol? 
10 mg (200 μl to each nostril) 
YES 
YES 
WAIT 45 MINUTES
WAIT 45 MINUTES
NO
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal vol? 
NO
20 mg to each nostril 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal vol? 
40 mg to each nostril 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal vol? 
100 mg orally 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal vol? 
200 mg orally 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal volume? 
Change in symptoms? * 
Greater than 25% variation in 
Amin or nasal volume? 
YES 
YES 
YES 
YES 
NO 
NO 
NO 
WAIT 45 MINUTES 
NO 
WAIT 45 MINUTES 
WAIT 45 MINUTES 
WAIT 45 MINUTES 
Aspirin tolerant 
Positive result 
* VAS, acoustic rhinometry, 
spirometry, NIPF, eNO, nNO, 
nasendoscopy… 
Fig. 2. Challenge procedure.
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was given an extra higher dose of lysine aspirin after he
had begun to react. Subsequently, we avoided challenging
patients with grossly obstructive polyps.
Nasal inspiratory peak ﬂow (NIPF) fell more than
40% in only 15 of 51 (15.7%) patients at the stage
where they were positive on acoustic rhinometry, with
a 25% decrease in Amin and /or volume 0–12 cm.
Reproducibility of the nasal challenge was good: 81
of 83 patients who took a second nasal application of
lysine aspirin 24 h later at the dose to which they were
previously positive noted a recurrence of their nasal
symptoms and upper airway obstruction.
Discussion
There is a need for ENT surgeons, allergists and chest
physicians to diagnose aspirin sensitivity safely, since
there is a need to inform those who need to avoid COX-
1 antagonists and to enable the non-aspirin-sensitive to
use such medications. Low dose aspirin reduces cardio-
vascular morbidity and mortality and is also protective
against many cancers [18, 19]. Unfortunately, no in vitro
method has a sufﬁciently high sensitivity and speciﬁcity
[9], which means that aspirin challenges should be
undertaken. Various routes are available: oral, bron-
chial, nasal and intravenous [10–12, 20]. Oral challenges
are expensive and time- consuming, requiring admission
of the patient and the initiation of an intravenous infu-
sion since they can be dangerous with severe prolonged
asthma exacerbations. The other routes all employ lysine
aspirin, the only truly soluble form of aspirin. Bronchial
challenges require specialized equipment usually
unavailable outside the respiratory department and can
also result in severe asthma [11]. Intravenous challenges
are performed in Japan only and are no faster than topi-
cal administration, but carry signiﬁcant risks [20].
In the ENT setting, there is the speciﬁc need and the
easy accessibility to target nasal polyps. The adminis-
tration of intra-nasal lysine aspirin constitutes the most
suitable route to challenge these patients.
In addition, nasal challenge offers a relatively simple
and safe method for diagnosis since direct application
to sensitive tissue occurs, the reaction is easily moni-
tored and, although it produces an increase in nasal
symptoms, does not compromise patient safety. The
most sensitive individuals are diagnosed using low
doses and only the more tolerant need to go on to be
challenged orally, thus avoiding hospital bed use. Our
small series rules out major adverse events with a rate
of 2%, rare events could still occur so close monitoring
of these patients by an experienced physician is neces-
sary.
A method of measuring the nasal airway is vital,
since subjective assessment is unreliable. If NIPF were
the only available method of monitoring the airway
then the 36 subjects who were diagnosed as positive on
acoustic rhinometry, but whose NIPF had not fallen
40%, as recommended in guidelines [10], would have
required further doses of lysine aspirin,with possible
worsening of symptoms.
Therefore, we suggest that NIPF is insufﬁciently sen-
sitive and acoustic rhinometry should be employed
when aspirin challenge is an outpatient procedure. Rhi-
nomanometry (GM Instruments, Kilwinning, Scotland)
is not likely to be helpful if the nose is more than mini-
mally blocked at the start of challenge since it is difﬁ-
cult to appreciate changes in the airway when the
initial ﬂow/pressure curve is ﬂattened [16].
Patient selection is vital with those with a history of
very severe immediate-type reactions being excluded as
well as those with non-respiratory symptoms in
response to aspirin. It is also necessary to have a nasal
airway which is capable of being measured and of
being reduced by aspirin so hyper-reactors and the
nasally completely occluded patients need treatment to
remedy these prior to challenge. Asthma control should
be established prior to challenge and asthma medica-
tions continued.
Our experience over several years shows that nasal
challenge is well tolerated and is capable of diagnosing
the majority of positive patients (59% in this study)
within 3–4 stepwise administrations a process taking
around 3–4 h. A further 29% react at higher nasal
doses, leaving only a few (12%) remaining genuinely
aspirin-sensitive individuals to be picked up by oral
challenge. This whole procedure can be ﬁtted into
1 day, provided a start is made in the morning. Three
of our four patients needed to return to complete the
challenge because of a late start due to long distance
travel.
One individual had a negative challenge result,
despite a strongly positive history of aspirin-sensitivity.
This is not entirely surprising as it is known that the
clinical history alone is not fully reliable for the diag-
nosis of aspirin sensitivity [7] and the patient had taken
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LAS challenge in nasal polyposis 879other drugs at the same time. The importance of co-fac-
tors such as underlying infection, exercise or alcohol
could have contributed to the original reaction and
may have to be taken into consideration. Discounting a
mistaken history, this could represent a false negative
result due to nasal steroid use or loss of aspirin sensi-
tivity which has been previously reported but is rare. A
second challenge after more prolonged abstention from
nasal steroids is advisable. Although female gender has
been shown to be a risk factor for AERD [2] in our
cohort of patients both sexes were equally affected.
The careful use of nasal lysine aspirin challenges in
an ENT setting, with co-operation from respiratory phy-
sicians, is possible and would improve the detection
rate of aspirin-exacerbated respiratory disease, an
under-recognized disorder.
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